Placebo (n=41) | CAP-1002 group (n=83) | P value | |
Age, mean (SD) | 53.5 (10.2) | 54.7 (11.1) | 0.56 |
Male gender, n (%) | 36 (87.8) | 72 (86.7) | 0.99 |
Chronicity of MI, n (%) | |||
Recent | 17 (41.5) | 37 (44.6) | 0.85 |
Chronic | 24 (58.5) | 46 (55.4) | |
Race, n (%) | |||
White | 34 (82.9) | 73 (87.9) | 0.17 |
Black or African-American | 6 (14.6) | 7 (8.4) | |
Asian | 0 | 3 (3.6) | |
American-Indian or Alaska Native | 1 (2.4) | 0 | |
Diabetes mellitus, n (%) | 11 (26.8) | 18 (21.7) | 0.65 |
Hypertension, n (%) | 27 (65.8) | 48 (57.8) | 0.70 |
ACE inhibitors or ARBs, n (%) | 35 (85.4) | 76 (91.6) | 0.35 |
Beta blockers, n (%) | 40 (97.6) | 79 (95.2) | 0.99 |
Diuretics, n (%) | 18 (43.9) | 34 (41.0) | 0.85 |
Aldosterone antagonists, n (%) | 12 (29.3) | 28 (33.7) | 0.69 |
Antithrombotic agents, n (%) | 41(100) | 81 (97.6) | 0.99 |
Lipid lowering agents, n (%) | 39 (95.1) | 79 (95.2) | 0.99 |
Aspirin, n (%) | 41(100) | 78 (93.4) | 0.17 |
ARB, angiotensin receptor blocker; MI, myocardial infarction.